SummerHaven Investment Management LLC Boosts Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

SummerHaven Investment Management LLC grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1.1% in the fourth quarter, Holdings Channel reports. The firm owned 34,034 shares of the specialty pharmaceutical company’s stock after acquiring an additional 368 shares during the period. Collegium Pharmaceutical accounts for approximately 0.7% of SummerHaven Investment Management LLC’s holdings, making the stock its 21st largest position. SummerHaven Investment Management LLC’s holdings in Collegium Pharmaceutical were worth $1,048,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its position in shares of Collegium Pharmaceutical by 68.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after buying an additional 883,380 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of Collegium Pharmaceutical by 178.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company’s stock valued at $9,513,000 after purchasing an additional 272,565 shares during the last quarter. New York State Common Retirement Fund raised its position in Collegium Pharmaceutical by 1,475.5% during the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock worth $6,190,000 after buying an additional 188,347 shares during the last quarter. Qube Research & Technologies Ltd raised its position in Collegium Pharmaceutical by 713.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 127,010 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after buying an additional 111,394 shares during the last quarter. Finally, Federated Hermes Inc. raised its position in Collegium Pharmaceutical by 76.0% during the 4th quarter. Federated Hermes Inc. now owns 212,768 shares of the specialty pharmaceutical company’s stock worth $6,549,000 after buying an additional 91,911 shares during the last quarter.

Collegium Pharmaceutical Price Performance

Shares of COLL traded up $0.48 during midday trading on Monday, reaching $36.90. The stock had a trading volume of 37,042 shares, compared to its average volume of 422,552. The firm’s 50 day moving average price is $37.14 and its 200-day moving average price is $31.37. The company has a market capitalization of $1.21 billion, a P/E ratio of 30.86 and a beta of 1.03. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.17 and a quick ratio of 1.10. Collegium Pharmaceutical, Inc. has a 52 week low of $20.83 and a 52 week high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.20 by $0.25. The firm had revenue of $149.75 million during the quarter, compared to analysts’ expectations of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. On average, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on COLL. Piper Sandler reissued an “overweight” rating and set a $39.00 price target (up from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. StockNews.com raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 23rd. Jefferies Financial Group reaffirmed a “hold” rating and set a $37.00 price objective (up previously from $30.00) on shares of Collegium Pharmaceutical in a research note on Thursday, January 4th. Truist Financial raised their price objective on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $40.00 price target on shares of Collegium Pharmaceutical in a research note on Thursday, April 11th. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $39.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.